Dorucin contains liposomal doxorubicin, a formulation of the anthracycline antibiotic doxorubicin encapsulated in liposomes. It is designed to improve the delivery of the drug to cancer cells while reducing the risk of damage to healthy tissue. Liposomal encapsulation alters the drug's pharmacokinetics, enhancing its efficacy and safety.

Uses

• Breast Cancer

• Ovarian Cancer

• Multiple Myeloma (in combination with other drugs)

• Kaposi's Sarcoma in patients with HIV/AIDS

Mechanism of Action

Liposomal doxorubicin intercalates into DNA, disrupting topoisomerase II activity, and inhibits DNA replication and RNA transcription. The liposomal delivery system allows prolonged circulation and targeted accumulation in tumor tissues, minimizing systemic toxicity.

Dosage and Administration

• Breast Cancer and Ovarian Cancer: 50 mg/m² intravenously every 4 weeks.

• Multiple Myeloma: 30 mg/m² intravenously on day 4 of a 28-day cycle (with bortezomib).

• Kaposi's Sarcoma: 20 mg/m² intravenously every 2 to 3 weeks.

Administration should be performed under the supervision of a healthcare professional experienced in chemotherapy.

Side Effects

Common side effects include:

• Fatigue

• Nausea

• Vomiting

• Hair loss

• Stomatitis (mouth sores)

Serious side effects:

• Cardiotoxicity

• Hand-foot syndrome

• Infusion-related reactions

Precautions

• Cardiac Monitoring: Regular echocardiograms to detect heart function changes.

• Bone Marrow Suppression: Monitor blood counts frequently.

• Infusion Reactions: Be prepared to manage hypersensitivity.

Onset and Duration of Action

• Onset: Begins action within a few hours after infusion.

• Duration: Therapeutic effects persist depending on treatment cycles.

Storage

• Store in a refrigerator between 2°C and 8°C.

• Do not freeze.

• Protect from light.